| scholarly article | Q13442814 |
| P50 | author | Daniel J. Sargent | Q43055483 |
| Hanna K Sanoff | Q89113920 | ||
| P2093 | author name string | Howard McLeod | |
| Richard M Goldberg | |||
| Erin Green | |||
| Roscoe F Morton | |||
| Jan Buckner | |||
| P2860 | cites work | Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program | Q35009894 |
| Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. | Q37325078 | ||
| A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin | Q44177901 | ||
| Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment | Q44820379 | ||
| Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma | Q44913737 | ||
| Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. | Q44916555 | ||
| Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. | Q45095320 | ||
| Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. | Q45242224 | ||
| Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. | Q46817228 | ||
| Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer | Q53294514 | ||
| Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Tri | Q79930433 | ||
| Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer | Q80455371 | ||
| Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 | Q80768425 | ||
| UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters | Q80865711 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study | Q28189472 | ||
| Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials | Q31026840 | ||
| Rapid reporting and review of an increased incidence of a known adverse event | Q33180566 | ||
| Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer | Q33372496 | ||
| Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 | Q33383727 | ||
| Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer | Q33414068 | ||
| Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. | Q33791812 | ||
| Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer | Q33810043 | ||
| Cost implications of new treatments for advanced colorectal cancer. | Q33874203 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. | Q34049406 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel | Q34371152 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| P433 | issue | 10 | |
| P921 | main subject | phase III clinical trial | Q42824827 |
| P304 | page(s) | 970-978 | |
| P577 | publication date | 2009-10-14 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial | |
| P478 | volume | 14 |
| Q35689948 | Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice |
| Q39628955 | Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research |
| Q35623336 | Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells |
| Q30416509 | Data for cancer comparative effectiveness research: past, present, and future potential |
| Q47257299 | Mortality within 30 days of receiving systemic anti-cancer therapy at a regional oncology unit: what have we learned? |
| Q37325674 | Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance |
| Q34716556 | Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials |
| Q48522724 | Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse Events |
Search more.